ASXL1 and breast cancer: Since, patients with CP who subsequently developed BC were more likely to harbour mutations, such as ASXL1 mutations, compared to those who did not harbour such mutations, and because BC patients with ASXL1 mutations had a poor prognosis, CP patients harbouring ASXL1 mutations may require careful management.